CANUCK LAW
Reporting That You're Not Getting Elsewhere (Do Your Own Research To Verify)

JANUARY 6, 2021 BY RONNIE

AstraZeneca, Another Candidate To Vaccinate Canadians, And The World

Registration - In-house Corporation
AstraZeneca Canada Inc. / Jane Chung, President
Registration Information
In-house Corporation name: AstraZeneca Canada Inc.
Responsible Officer Name: Jane Chung, President
Responsible Officer Change History
Initial registration start date: 2007-03-08
Registration status: Active
Registration Number: 944875-15042
Registration versions: 42 of 42: 2020



Applicant	Medicinal ingredient(s)	Therapeutic area	was received	Outcome of application	Date of decision/outco
AstraZeneca Canada Inc.	Adenovirus vaccine vector (ChAdOx1)	Vaccines, for human use	2020-10-01	Under review	n/a
Dr Reddys Laboratories Ltd	Favipiravir	Antivirals for systemic use, for human use	2020-12-18	Under review	n/a
Eli Lilly Canada Inc	Bamlanivimab (LY-CoV555)	Immune sera and immunoglobulins, for human use	2020-10-12	Authorized (with terms and conditions)	2020-11-20
Gilead Sciences Canada Inc.	Remdesivir	Antivirals for systemic use, for human use	2020-06-19	Authorized (with conditions)	2020-07-27
Janssen Inc	JNJ-78436735/Ad26.COV2.S	Vaccines, for human use	2020-11-30	Under review	n/a
Moderna Therapeutics Inc.	mRNA-1273 SARS-CoV-2	Vaccines, for human use	2020-10-12	Authorized (with terms and conditions)	2020-12-23
Pfizer Canada	Tozinameran (mRNA	Vaccines, for	2020-10-09	Authorized (with	2020-12-09

AstraZeneca is one of the pharmaceutical companies looking to sell large quantities of vaccines to Canada, for a virus that has a 99% survival rate. One has to wonder what the public isn't being told.

1. AstraZeneca Lobbied M-132 Cmte Vice-Chair

Media error: Format(s) not supported or source(s) not found

Download File: https://canucklaw.ca/wp-content/uploads/2020/04/Speech-on-M-132-Federally-Funded-Health-Research-Lloyd-Longfield-Member-of-Parliament-for-Guelph_2aYUni_eU9I_240p.mp4?_=1

Monthly Communication Report

Return to Registration for AstraZeneca Canada Inc.

15042-422583

Corporation:	**AstraZeneca Canada Inc.**
Associated registration:	934857-15042-34
Communication date:	2018-02-08
Posted date:	2018-03-16
Designated Public Office Holders who participated in the communication:	**Marilyn Gladu**, Member of Parliament House of Commons

Monthly Communication Report

Return to Registration for AstraZeneca Canada Inc.

15042-422578

Corporation:	**AstraZeneca Canada Inc.**
Associated registration:	934857-15042-34
Communication date:	2018-03-08
Posted date:	2018-03-16
Designated Public Office Holders who participated in the communication:	**Marilyn Gladu**, Member of Parliament House of Commons

Monthly Communication Report

Return to Advanced Registry Search Results

15042-443766

Corporation:	**AstraZeneca Canada Inc.**
Associated registration:	934857-15042-34
Communication date:	2018-12-03
Posted date:	2019-01-15
Designated Public Office Holders who participated in the communication:	**Marilyn Gladu**, Member of Parliament House of Commons

Motion Text

That the Standing Committee on Health be instructed to undertake a study on ways of increasing benefits to the public resulting from federally funded health research, with the goals of lowering drugs costs and increasing access to medicines, ***both in Canada and globally***; and that the Committee report its findings and recommendations to the House no later than one year from the time this motion is adopted.

Remember Motion M-132? It was the Motion introduced in 2017 to finance drugs and drug research both for Canada and the world. See here and here. Marilyn Gladu was the Vice-Chair on that Committee, and hence, lobbying her would carry significant weight.

2. David Lametti Lobbied By AstraZeneca

Monthly Communication Report

Return to Registration for AstraZeneca Canada Inc.

15042-385474

Corporation:	**AstraZeneca Canada Inc.**
Associated registration:	906444-15042-28
Communication date:	2016-09-28
Posted date:	2016-10-14
Designated Public Office Holders who participated in the communication:	**David Lametti**, Partliamentary Secretary International Trade, Global Affairs Canada (GAC)



Monthly Communication Report

Return to Registration for AstraZeneca Canada Inc.

15042-405583

Corporation:	**AstraZeneca Canada Inc.**
Associated registration:	906444-15042-31
Communication date:	2017-06-22
Posted date:	2017-07-14
Designated Public Office Holders who participated in the communication:	**David Lametti**, Parliamentary Secretary to the Mininister of ISED Innovation, Science and Economic Development Canada (ISED)

	AstraZeneca Canada Inc.
stration:	934857-15042-34
date:	2018-10-23
	2018-11-15
lic Office Holders d in the	**John Knubley**, Deputy Minister Innovation, Science and Economic Development Canada (ISED) **Lloyd Longfield**, Member of Parliament / Member INDU Committee & Chair of Innovation and Technology Caucus House of Commons **Daniel Albas**, Member of Parliament / Opposition Innovation, Science & Economic Development Critic House of Commons **Giancarlo Cairo**, Chief of Staff for Minister ISED Innovation, Science and Economic Development Canada (ISED) **David Lametti**, Member of Parliament / Parliamentary Secretary to the Minister of ISED Innovation, Science and Economic Development Canada (ISED)

During the years of 2016 to 2018, David Lametti was a Parliamentary Secretary the Minister of Innovation, Science, and Economic Development. Since early 2019, however, he has been the Attorney General of Canada.


Search
Home
My Network
Jobs
Zakery Blais
Consultant at Crestview Strategy // Director Of Operations at Canadian American Business Council
Legislative Assistant to David Lametti, M.P./Parl Sec, Innovation, Science and Economic Development
House of Commons of Canada Chambre des communes du Canada
Apr 2016 – Jan 2018 · 1 yr 10 mos
Ottawa, Ontario
Show fewer experiences
Education
Queen's University
Master of Public Administration - MPA
2018 – 2019


Office of the Commissioner of Lobbying of Canada
Commissariat au lobbying du Canada
lobbycanada.gc.ca
Français
Registry of Lobbyists
Registry Search
Reporting Tools
Statistics
Support
Sign in
Registry Dashboard
Registration - Consultant
Share this page
Gavi, the Vaccine Alliance / Gavi, L'Alliance du Vaccin / Zakery Blais, Consultant
Registration Information
Client name: Gavi, the Vaccine Alliance / Gavi, L'Alliance du Vaccin
Lobbyist name: Zakery Blais, Consultant
Initial registration start date: 2019-08-19
Registration status: Active
Registration Number: 943004-365218
Associated Communications
Total Number of Communication Reports: 2
Monthly communication reports in the last 6 months: 0
Registration versions: 2 of 2: 2020-08-01 to present
Version 2 of 2 (2020-08-01 to present)


crestview strategy
WHAT WE DO
WHO WE ARE
Our Team
MEENA AIER
ASHTON ARSENAULT
MARINA BANISTER
ZAKERY BLAIS
ANDREW BRANDER
JESSICA BROWN
MELISSA CAOUETTE
NATHAN CARR
MORGAN CATES
ALEX CHRESTON
JASON CLARK
CHARLIE CRABB
HAL DANCHILLA
JORDAN DEVON
Zakery Blais
Zakery Blais is a Consultant with Crestview Strategy. With a focus on Canada-U.S. relations and international development, Zakery services clients globally.
His experience spans both the public and private sectors. He previously worked as a Legislative Assistant to a Canadian Member of Parliament, providing strategic political and communications advice. Prior to joining Crestview Strategy, Zakery also worked in various capacities

As addressed here, Zakery Blais was an Assistant to Lametti when he was a Parliamentary Secretary. Now, he works for the lobbying firm, Crestview Strategy, which was co-Founded by Rob Silver, Katie Telford's husband. Blais has been a lobbyist pushing for public money for his then client, GAVI

3. "Global Leader", Michelle Rempel-Garner



Monthly Communication Report

Return to Registration for AstraZeneca Canada Inc.

15042-483386

Corporation:	**AstraZeneca Canada Inc.**
Associated registration:	944875-15042-40
Communication date:	2020-09-16
Posted date:	2020-10-15
Designated Public Office Holders who participated in the communication:	**Michelle Rempel Garner**, Member of Parliament House of Commons

Monthly Communication Report

Return to Advanced Registry Search Results

14483-487696

Corporation:	**Janssen Inc. (Pharmaceutical Companies of Johnson & Johnson)**
Associated registration:	944618-14483-28
Communication date:	2020-11-13
Posted date:	2020-11-14
Designated Public Office Holders who participated in the communication:	**Michelle Rempel**, Member of Parliament House of Commons



Monthly Communication Report

Return to Advanced Registry Search Results

354-477719

Organization:	**BIOTECANADA**
Associated registration:	836594-354-31
Communication date:	2020-06-23
Posted date:	2020-07-15
Designated Public Office Holders who participated in the communication:	**Michelle Rempel**, Member of Parliament House of Commons

Monthly Communication Report

Return to Advanced Registry Search Results

15283-491596

Corporation:	**Pfizer Canada ULC**
Associated registration:	945525-15283-28
Communication date:	2020-11-27
Posted date:	2020-12-15
Designated Public Office Holders who participated in the communication:	**The Honorable Michelle Rempel-Garner**, Member of Parliament for Calgary-Nose House of Commons **The Honorable Erin O'Toole**, Leader of the Official Opposition, Member of Parliament House of Commons

Michelle holds a degree in economics. Highlights of her many honours include being named one of Canada's Top 100 Most Powerful Women by the Women's Executive Network, ***Calgary's "Top 40 under 40", and being named twice by Maclean's Magazine as their Parliamentarian of the Yea***r – Rising Star calling her "one of the government's most impressive performers." ***Michelle is also a Young Global Leader***, invited to be so by the World Economic Forum. The ***World Economic Forum calls the Forum of Young Global Leaders*** a "unique and diverse community of the world's most outstanding, next generation leaders." Rempel was also recently named one of "Alberta's 50 Most Influential People".



00:00 02:40

Although the link seems disabled, Rempel is held in high regards by the World Economic Forum. She is part of the Young Global leaders. This raises the legitimate question of who she really serves. Information is also available on her website.

When Rempel-Garner openly and publicly calls for the entire Canadian population to be vaccinated, who's really speaking? Is it her, or the drug companies who lobby her?

4. AZ Pushing Canada For GLOBAL Pharma


n Details
Lobbyists Details
Subject Matter Details
Policies or Program
Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe

Government of Canada
Gouvernement du Canada
Français
Search Canada.ca
MENU
Canada.ca > Departments and agencies > Health Canada > Services
Canada's Access to Medicines Regime
Canada's Access to Medicines Regime provides a way for the world's developing and least-developed countries to import high-quality drugs and medical devices at a lower cost to treat the diseases that bring suffering to their citizens. It is one part of the Government of Canada's broader strategy to assist countries in their struggle against HIV/AIDS, tuberculosis, malaria and other diseases.
This website has all of the information that developing and least-developed countries, non-governmental organizations and pharmaceutical companies need to take advantage of the Regime.
Find out more about Canada's Access to Medicines Regime and how your country or company can benefit from it.
Introduction
Countries

> ***Canada's Access to Medicines Regime*** provides a way for the ***world's developing and least-developed countries to import high-quality drugs and medical devices at a lower cost*** to treat the diseases that bring suffering to their citizens. It is one part of the

> Government of Canada's broader strategy to assist countries in their struggle against HIV/AIDS, tuberculosis, malaria and other diseases.

Just so we're clear on what's going on, AstraZeneca is pushing for Canada to buy vaccines so that they can be provided at little or no cost to the 3rd World. In short, Canadian taxpayers would be on the hook for vaccinating other countries. Of course, this is in addition to getting a domestic supply.

And what about their lobbyists over the years?

> Public offices held: Tara Bingham
> Executive Assistant and Special Assistant for Parliamentary Affairs & Communications, Hon. Belinda Stronach, M.P., 2004-2005
> Parliamentary Assistant, Grant McNally, M.P., 1999-2004
> Researcher, Office of the Leader of the Opposition, Preston Manning, M.P., 1997-1999

> Public offices held: William Charnetski
> Special Advisor, The Honourable Allan Rock, Q.C., P.C., M.P., Minister of Justice and Attorney General of Canada, 1995-1996
> Executive Assistant, William C. Graham, Q.C., Member of Parliament (Rosedale), 1993-1995

> Public offices held: Marie-Chantale Lepine
> Director of Communications, Rt. Hon. Joe Clark, M.P., 2001-2002

Ties to both the Liberal Party of Canada, and the Conservatives. In this case, it doesn't seem to matter who is in power.

5. Who Are AstraZeneca's Lobbyists?

Responsible Officer Change History

AstraZeneca Canada Inc.

Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Jane Chung	2019-11-01	Current
Daniel Smedley	2019-08-01	2019-11-01
Jamie Freedman	2017-11-28	2019-08-01
Ed Dybka	2015-01-02	2017-11-28
Elaine Campbell	2012-01-09	2015-01-02
Marion McCourt	2010-04-12	2012-01-09
Mark Jones	2007-03-08	2010-04-12


Search
Home
My Network
Jobs
Jane Chung
President, AstraZeneca Canada
Experience
AstraZeneca
5 yrs 9 mos
President, AstraZeneca Canada
Nov 2019 – Present · 1 yr 3 mos
Toronto, Ontario, Canada
VP, Head of US Immuno-Oncology, Sales and Marketing
Feb 2017 – Nov 2019 · 2 yrs 10 mos
Washington D.C. Metro Area
Led commercialization in building 1B US ImmunoOncology business.
Sr. Commercial Business Director - Oncology
May 2015 – Feb 2017 · 1 yr 10 mos
San Francisco Bay Area
Delivered top Region performance, leading 6 sales managers and 50+ sales representatives.
Onyx Pharmaceuticals, Inc., an Amgen subsidiary
2 yrs 1 mo
Region Sales Director - Oncology
Feb 2015 – May 2015 · 4 mos
San Francisco Bay Area





https://archive.is/ypVdu

6. More Lobbying By AstraZeneca

Search Results

Lobbyist	Last Amendment Date	Client Name	Company/Organization
Elizabeth Lye	12/04/2020		AstraZeneca Canada Inc.
France Dube	12/04/2020		AstraZeneca Canada Inc.
Ilias Iliopoulos	12/04/2020		AstraZeneca Canada Inc.
Jane Chung	12/04/2020		AstraZeneca Canada Inc.
Jon Fearis	12/04/2020		AstraZeneca Canada Inc.
Mo Amin	12/04/2020		AstraZeneca Canada Inc.
Nadia Yee	12/04/2020		AstraZeneca Canada Inc.
Noel Saraza	12/04/2020		AstraZeneca Canada Inc.
France Dube	01/15/2018		AstraZeneca Canada Inc.
Jon Fearis	01/15/2018		AstraZeneca Canada Inc.
Karen Heim	01/15/2018		AstraZeneca Canada Inc.
Nadia Yee	01/15/2018		AstraZeneca Canada Inc.
Noel Saraza	01/15/2018		AstraZeneca Canada Inc.
Ed Dybka	07/26/2016		AstraZeneca Canada Inc.
Jonathan Fearis	07/05/2016		AstraZeneca Canada Inc.
Lisa Marsden	07/05/2016		AstraZeneca Canada Inc.
Brian Maloney	05/26/2016		AstraZeneca Canada Inc.
Elaine Campbell	01/28/2015		AstraZeneca Canada Inc.
Martin McNeil	10/16/2014		AstraZeneca Canada Inc.
James Wallace	09/08/2014		AstraZeneca Canada Inc.

1 2 Page size: 20

1 - 15 of 15

Filing Date	Termination Date	Organization	Client Name	Designated Filer
04-Dec-2020	-	AstraZeneca Canada Inc.	-	Jane Chung
19-Oct-2020	-	AstraZeneca Canada Inc.	-	Jane Chung
30-Jun-2020	-	AstraZeneca Canada Inc.	-	Jane Chung
24-Apr-2020	-	AstraZeneca Canada Inc.	-	Jane Chung



Search Parameters

Keyword: astrazeneca
Registration Status: Active, Active Non-compliant

Show 50 entries

Client/Organization	Lobbyist/Senior Officer	Status	Type	Version	Effective
Innovative Medicines Canada	Pamela Fralick	Active	In-House	13 of 13	2020-11-18
AstraZeneca Canada Inc.	Jane Chung	Active	In-House	13 of 13	2020-11-01

Showing 1 to 2 of 2 entries Previous



New Registrations Results
17 results found

Name	Registration Role	Client/Organization	Registration Status	Date Registration Ent Status
Campbell, Elaine	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	July 16, 2013
Campbell, Elaine	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	July 23, 2014
Campbell, Elaine	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	January 22, 2014
Campbell, Elaine	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	January 14, 2013
Chung, Jane	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	June 02, 2020
Chung, Jane	Senior Officer	ASTRAZENECA CANADA INC.	Active	December 07, 2020
Chung, Jane	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	November 15, 2019
Chung, Jane	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	December 04, 2020
Dybka, Ed	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	September 20, 2016
Dybka, Ed	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	January 28, 2015
Dybka, Ed	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	March 31, 2017
Dybka, Ed	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	October 03, 2017
Dybka, Ed	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	March 02, 2016
Dybka, Ed	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	August 26, 2015
Freedman, Jamie	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	May 13, 2019
Freedman, Jamie	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	April 24, 2018
Freedman, Jamie	Senior Officer	ASTRAZENECA CANADA INC.	Terminated	October 30, 2018

Back

From the Alberta, Saskatchewan, Manitoba and Ontario Registries.

7. Who Runs AstraZeneca?

- Pascal Soriot, Executive Director and CEO
- Marc Dunoyer, Executive Director and CFO
- Katarina Ageborg, Executive Vice-President, Sustainability and Chief Compliance Officer; President AstraZeneca AB, Sweden
- José Baselga, Executive Vice-President, Oncology R&D
- Pam Cheng, Executive Vice-President, Operations and Information Technology
- Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit
- David Fredrickson, Executive Vice-President, Oncology Business Unit
- Menelas (Mene) Pangalos, Executive Vice-President, BioPharmaceuticals R&D

- Jeff Pott, Executive Vice-President, Human Resources and General Counsel
- Iskra Reic, Executive Vice-President, Europe and Canada
- Leon Wang, Executive Vice-President, International

https://www.astrazeneca.com/our-company/leadership.html

8. AstraZeneca Ordered To Pay Money

THE UNITED STATES DEPARTMENT of JUSTICE

ABOUT OUR AGENCY PRIORITIES NEWS RESOURCES CAREER

Home » Office of Public Affairs » News

JUSTICE NEWS

Department of Justice

Office of Public Affairs

FOR IMMEDIATE RELEASE Wednesday, February 11, 2015

AstraZeneca to Pay $7.9 Million to Resolve Kickback Allegations

AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, has agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act, the Justice Department announced today. AstraZeneca markets and sells pharmaceutical products in the United States, including a drug sold under the trade name Nexium.

AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, ***has agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act***, the Justice Department announced today. AstraZeneca markets and sells pharmaceutical products in the United States, including a drug sold under the trade name Nexium.

"We will continue to ***pursue pharmaceutical companies that pay kickbacks to pharmacy benefit managers***," said Acting Assistant Attorney General Joyce R. Branda of the Justice Department's Civil Division. ***"Hidden financial agreements between drug manufacturers and pharmacy benefit managers can improperly influence which drugs are available to patients and the price paid for drugs***."

The settlement resolves allegations that AstraZeneca agreed to provide remuneration to Medco Health Solutions, a pharmacy benefit manager, in exchange for Medco maintaining

> Nexium's "sole and exclusive" status on certain Medco formularies and through other marketing activities related to those Medco formularies. The United States alleged that AstraZeneca provided some or all of the remuneration to Medco through price concessions on drugs other than Nexium, namely on Prilosec, Toprol XL and Plendil. The United States contended that this kickback arrangement between AstraZeneca and Medco violated the Federal Anti-Kickback statute, and thereby caused the submission of false or fraudulent claims for Nexium to the Retiree Drug Subsidy Program.

In 2003, AstraZeneca had to pay $355 million to resolve criminal charges and civil liabilities related to marketing practices and drug pricing.

In 2010, AstraZeneca was forced to pay $520 million to for a fraud case that involved allegations of bribery and kickbacks in order to push schizophrenic medications.

In 2015, AstraZeneca was ordered to pay $7.9 million in a kickback scheme. Seems that the finances weren't exactly on the level.

AstraZeneca has also been in Canadian courts many times, often involving patents and intellectual property disputes.

CANADA, GLOBALISM, LOBBYING, NGO/CS, VACCINES